Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Individualized treatment of left and right

    2020-08-12


    Individualized treatment of left and right colon cancer is mainly reflected in chemotherapy. A CALGB / SWOG 80405 phase III clinical trial [18] showed that, in RAS wild-type mCRC, when tumors were located in the left colon, the overall survival time of cetuximab treatment was longer than that OSMI4 of bevacizumab, and when tumors were located in the right colon, the overall survival time of cetuximab treatment was shorter than that of bevacizumab treatment. With further studying the potential differences between left and right colon cancer, the treatment of colon cancer will be more precise and individualized in the future.
    Although the correlation between the primary site of tumor and the prognosis of colorectal cancer is still controversial, most scholars believe that the primary site of tumor is an independent factor in the prognosis of CRC. Previous studies have shown
    ACCEPTEDthatcomparedwithLCC,RCChasasignificantly lower mean survival time and 5-year survival rate. A research conducted by Benedix et al. showed that patients with RCC
    had a worse prognosis than LCC[19]. Besides, data from the Surveillance, Epidemiology, and End Results Program (SEER) database showed that the median survival of colon cancer was 83 months, and the median survival of right and left colon cancers were 78 and 89 months, respectively. The difference between the two groups was statistically significant (P<0.05)[20]. In our study, the median survival of patients with RCC, LC and RC were 72, 70 and 73 months, respectively. The median survival of the three groups was statistically significant (P=0.049). Therefore, the results of the study were inconsistent with previously published ones, which could be caused by inadequate sample size and loss of follow-up. In addition, surgical methods (laparoscopic or open surgery) and surgical types (radical or palliative resection) could
    Authors’ contributions
    also have an impact on the results.
    In conclusion, colorectal cancer at different anatomical subsites exhibits different epidemiological and clinicopathological features. The age of onset of right-sided colon cancer is the oldest on average and poorly differentiated tumors accounted for the highest proportion. Besides, average maximum tumor diameter is the largest in right-sided colon cancer. Comprehensive understanding of the clinicopathological features
    and prognosis of colorectal cancer at differentMANUSCRIPTanatomicalsubsitesisofgreatguiding significance for clinical diagnosis and treatment of colorectal cancer, and is helpful for individualized treatment and precise treatment. According to our opinion, Corepressor is highly necessary to find and confirm the molecular biological differences of colorectal cancer at different anatomical subsites. Further studies are encouraged to investigate on this topic.
    Z.F and X.M.S. drafted the manuscript. Y.F.Z and S.Y.R. supervised the whole project.
    All authors read and approved the final manuscript.
    Funding
    This study was supported by the National Natural Science Foundation of China (81372669).
    Conflicts of interests
    The authors declare that there is no conflict of interests in this study.
    References:
    3. Saltzstein SL and CA Behling. Age and time as factors in the left-to-right shift
    of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the
    4. Nawa T, Kato J, Kawamoto H et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol, 2008. 23(3): 418-23.
    6. Mik M, Berut M, Dziki L et al. Right- and left-sided colon cancer - clinical and pathological differences of the disease entity in one organ. Arch Med Sci, 2017.
    7. Shen H, Yang J, Huang Q et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol, 2015. 21(21): 6470-8.
    9. Slattery ML, Friedman GD, Potter JD et al. description of age, sex, and site
    distributions of colon carcinoma in three geographic areas. Cancer, 1996. 78(8):
    10. Natsume S, Yamaguchi , Takao M et al. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Jpn J Clin Oncol, 2018. 48(7): 609-618.
    13. Ghazi S, Lindforss U, Lindberg G et al. Analysis of colorectal cancer morphology in relation to sex, age, location, and family history. J Gastroenterol,
    14. Minoo P, Zlobec I, Peterson M et al. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol, 2010. 37(3): 707-18.
    15. Shibutani M, Maeda K, Nagahara H et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Res, 2014. 34(7): 3753-8.